Isorhamnetin Alleviates Renal Fibrosis Induced by Renal Tubular Epithelial Cell Senescence Via Inhibition of the IL‐6/IL‐6R Signaling Pathway
iMetaMed · 2026-03 · 2 (1)
DOI: 10.1002/imm3.70028 ↗Abstract
ABSTRACT Chronic kidney disease (CKD) is a major global health issue. Kidney fibrosis is a key mechanism leading to end‐stage renal disease. Senescence of renal tubular epithelial cells (RTECs) and the senescence‐associated secretory phenotype (SASP) factors they release are crucial in kidney fibrosis progression. While isorhamnetin, the active component of Astragalus membranaceus , has demonstrated promise in combating senescence/aging and fibrosis, its precise mechanism of action remains poorly understood. This study aims to elucidate the mechanisms through which isorhamnetin mitigates RTEC senescence and kidney fibrosis, specifically by modulating the interleukin‐6 (IL‐6) signaling pathway. The findings indicate that isorhamnetin significantly attenuates kidney fibrosis in aging mice, inhibiting IL‐6 secretion from senescent RTECs and reducing its accumulation in kidney tissues. In vitro analyses further revealed that isorhamnetin disrupted IL‐6 signaling by competitively binding to the IL‐6 receptor, thereby slowing RTEC senescence. Additional investigations demonstrated that isorhamnetin's inhibition of IL‐6 secretion from senescent RTECs impacted macrophage M2 polarization and the transformation of fibroblasts into myofibroblasts, thus decelerating the progression of kidney fibrosis. This study highlights the critical role of isorhamnetin in alleviating RTEC senescence and kidney fibrosis through the suppression of the IL‐6 signaling pathway, underscoring its potential for clinical application in CKD treatment.
EUVIMED